Advancement in Genomic Testing to Contribute to Global Gene Expression Analysis Market

Global gene expression analysis market is anticipated to grow at a considerable CAGR of 8.6% during the forecast period (2024-2031). The ongoing advancement in genomic testing due to increased focus on the genome to treat chronic genetic disorders is a key factor driving the global market. For instance, in February 2024, NanoString Technologies, Inc. announced the commercial availability of the CosMx Human 6K Discovery Panel, the first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. 

Further, in January 2024, Thermo Fisher Scientific announced a next-generation Invitrogen TaqMan Cells-to-CT Express Kit, offering simplified, scalable workflows for gene expression analysis that produce less plastic waste. With improved chemistry, the Cells-to-CT Express Kit helps facilitate the preparation of cell lysates for reverse transcription (RT) real-time PCR (qPCR) in just five minutes.

Browse the full report description of “Gene Expression Analysis Market Size, Share & Trends Analysis Report By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Microarray), by Product (Instruments, Reagents & Consumables, and Services), By End-User (Drug Discovery and Development, Diagnostic Laboratories, and Academic Research Centers) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/gene-expression-analysis-market

Furthermore, in June 2023, Sarepta Therapeutics, Inc. received the US FDA accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval based on the expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Technology

o By Product

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Quest Diagnostics Inc., Illumina, Inc., PerkinElmer Inc., Agilent Technologies Inc., and Promega Corp. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gene Expression Analysis Market Report Segment

By Technology

• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Microarray

By Product

• Instruments
• Reagents & Consumables
• Services

By End-User

• Drug Discovery and Development
• Diagnostic Laboratories
• Academic Research Centers

Global Gene Expression Analysis Market Report Segment by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/gene-expression-analysis-market